Showing results (1211-1220 of 1,396) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|November 29, 2022
Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDEKatrina Walker, Samantha Hinsley, Rachel Phillip, et al.
JCO Precision Oncology|June 6, 2022
Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical PracticeTam Binh V Bui, Boudewijn M T Burgering, Andrei Goga, et al.
JCO Precision Oncology|December 8, 2022
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric CancersBrandon M Huffman, Vasily N Aushev, Griffin L Budde, et al.
JCO Precision Oncology|December 8, 2022
Germline Genetic and Treatment-Related Risk Factors for Diabetes Mellitus in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study and St Jude Lifetime CohortsMelissa A Richard, Sogol Mostoufi-Moab, Nisha Rathore, et al.
JCO Precision Oncology|May 11, 2022
Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical CareRyan J Summers, Sharon M Castellino, Christopher C Porter, et al.
JCO Precision Oncology|July 7, 2022
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor BenefitRomualdo Barroso-Sousa, Juliet Forman, Katharine Collier, et al.
JCO Precision Oncology|June 30, 2022
Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract CancerSavannah S Liddell, Sakti Chakrabarti, Grant A Wintheiser, et al.
JCO Precision Oncology|June 16, 2022
Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological DrugsJan Trøst Jørgensen
JCO Precision Oncology|September 11, 2020
Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable PhenotypeJordan Kardos, Sara E Wobker, Michael E Woods, et al.
JCO Precision Oncology|September 11, 2020
BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent AlterationsYuri Sheikine, Dean Pavlick, Samuel J Klempner, et al.
Pageof 140